Adracard
By Samuel Wines
5 March 2025
AdraCard is a pioneering company committed to transforming the management of anaphylaxis by addressing the limitations of current adrenaline delivery methods. Recognizing that traditional devices like EpiPens are often bulky, have a short shelf life, and are susceptible to temperature variations, AdraCard is developing a novel drug delivery platform. This innovative solution is designed to be compact and convenient, fitting seamlessly into daily life – whether in a wallet, on the back of a phone, or attached to a keyring – thereby eliminating the burden of carrying traditional auto-injectors and also removing the need for the needle.
Founded in 2021 by Liam Mahony and Lachlan Timms, AdraCard has rapidly advanced its mission to revolutionize allergy management. With the support of global experts, the company has made significant strides toward bridging the gap from research to commercialization, aiming to make burdensome auto-injectors a thing of the past.
By joining the CoLabs community, AdraCard is poised to further its impact, leveraging collaborative opportunities to enhance its innovative approach to anaphylaxis treatment. Together, we aim to support AdraCard’s mission to empower individuals with life-threatening allergies, ensuring they have access to life-saving solutions that are both practical and reliable.
Keen to learn more? Check them out here:
